Gestational diabetes mellitus (GDM) is any degree of glucose intolerance with onset or first recognition during pregnancy.
Hyperglycemia in pregnancy may be suggested by the presence of glycosuria, a fetus that is large for date, or polyhydramnios.
Overt diabetes mellitus may be found in women presenting with risk factors for type 2 diabetes during the first prenatal visit (before 13 weeks of gestation).
Gestational diabetes and abnormal glucose levels in pregnancy, as determined with an oral glucose challenge test (OGCT) at 24–28 weeks gestation, could signal a future risk of cardiovascular disease (CVD)*, according to a recent study.
Metformin continues to protect high-risk individuals from developing type 2 diabetes (T2D) over 15 years, especially among those with higher glycaemic status at baseline and women reporting a history of gestational diabetes mellitus (GDM), according to long-term results from DPP/DPPOS*.
Eating vegetable and protein before carbohydrate attenuated postprandial glucose response in healthy Asian adults, according to the PATTERN* study, suggesting that behavioural change in eating sequence may be a potential strategy for modulating glycaemic response.
The cardiovascular (CV) benefits of the SGLT2* inhibitor dapagliflozin extend across a broad spectrum of patients with type 2 diabetes (T2D) and high CV risk, in particular those with heart failure with reduced ejection fraction (HFrEF), reports a subanalysis of the DECLARE-TIMI 58 trial presented at ACC.19 Annual Scientific Session.
A lifestyle intervention combining dietary and physical activity counselling initiated during early pregnancy does not appear to effectively improve dietary intake, physical activity, or obstetric and perinatal outcomes in pregnant women at high risk of gestational diabetes mellitus, according to data from the RADIEL trial.